Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Income: 2017-2024

Historic Operating Income for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to -$45.6 million.

  • Kiniksa Pharmaceuticals International's Operating Income rose 348.72% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year increase of 245.43%. This contributed to the annual value of -$45.6 million for FY2024, which is 81.04% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Operating Income stood at -$45.6 million for FY2024, which was down 81.04% from -$25.2 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Operating Income ranged from a high of $9.8 million in FY2022 and a low of -$157.4 million during FY2020.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Operating Income value was -$25.2 million (recorded in 2023), while the average stood at -$20.3 million.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Operating Income spiked by 106.24% in 2022 and then plummeted by 357.81% in 2023.
  • Kiniksa Pharmaceuticals International's Operating Income (Yearly) stood at -$157.4 million in 2020, then climbed by 0.46% to -$156.6 million in 2021, then surged by 106.24% to $9.8 million in 2022, then slumped by 357.81% to -$25.2 million in 2023, then tumbled by 81.04% to -$45.6 million in 2024.